AAAAAA
Results:
1-14
|
Results: 14
Authors:
MOYLE GJ
GAZZARD BG
Citation: Gj. Moyle et Bg. Gazzard, FINDING A ROLE FOR ZALCITABINE IN THE HAART ERA, Antiviral therapy, 3(3), 1998, pp. 125-137
Authors:
MOYLE GJ
GAZZARD BG
Citation: Gj. Moyle et Bg. Gazzard, LAMIVUDINE IN THE MANAGEMENT OF ADULTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION, Antiviral therapy, 3(1), 1998, pp. 7-18
Authors:
SULLIVAN AK
NELSON MR
MOYLE GJ
NEWELL AM
FEHER MD
GAZZARD BG
Citation: Ak. Sullivan et al., CORONARY-ARTERY DISEASE OCCURRING WITH PROTEASE INHIBITOR THERAPY, International journal of STD & AIDS, 9(11), 1998, pp. 711-712
Authors:
MOYLE GJ
GILL J
NELSON M
Citation: Gj. Moyle et al., ONCE WEEKLY AZITHROMYCIN AS PROPHYLAXIS AGAINST RECURRENCE OF NONTUBERCULOUS MYCOBACTERIAL INFECTIONS IN HIV-1-POSITIVE INDIVIDUALS, AIDS, 12(12), 1998, pp. 1555-1557
Authors:
MOYLE GJ
YOULE M
HIGGS C
MONAGHAN J
PRINCE W
CHAPMAN S
CLENDENINN N
NELSON MR
Citation: Gj. Moyle et al., SAFETY, PHARMACOKINETICS, AND ANTIRETROVIRAL ACTIVITY OF THE POTENT, SPECIFIC HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE INHIBITOR NELFINAVIR - RESULTS OF A PHASE I II TRIAL AND EXTENDED FOLLOW-UP IN PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS/, Journal of clinical pharmacology, 38(8), 1998, pp. 736-743
Authors:
MOYLE GJ
GAZZARD BG
COOPER DA
GATELL J
Citation: Gj. Moyle et al., ANTIRETROVIRAL THERAPY FOR HIV-INFECTION - A KNOWLEDGE-BASED APPROACHTO DRUG SELECTION AND USE, Drugs, 55(3), 1998, pp. 383-404
Authors:
MOYLE GJ
Citation: Gj. Moyle, CURRENT KNOWLEDGE OF HIV-1 REVERSE-TRANSCRIPTASE MUTATIONS SELECTED DURING NUCLEOSIDE ANALOG THERAPY - THE POTENTIAL TO USE RESISTANCE DATATO GUIDE CLINICAL DECISIONS, Journal of antimicrobial chemotherapy, 40(6), 1997, pp. 765-777
Authors:
MOYLE GJ
GAZZARD BG
Citation: Gj. Moyle et Bg. Gazzard, SURROGATE MARKERS NOW PROVIDE PHYSICIANS WITH THE BEST MEANS TO MANAGE ANTIRETROVIRAL THERAPY - THE CASE FOR, Genitourinary medicine, 73(3), 1997, pp. 216-218
Authors:
GAZZARD BG
MOYLE GJ
WEBER J
JOHNSON M
BINGHAM JS
BRETTLE R
CHURCHILL D
FISHER M
GRIFFIN G
JEFFERIES D
KING E
GORMER R
LEE C
POZNIAK A
SMITH JR
TUDORWILLIAMS G
WILLIAMS I
Citation: Bg. Gazzard et al., BRITISH HIV ASSOCIATION GUIDELINES FOR ANTIRETROVIRAL TREATMENT OF HIV-SEROPOSITIVE INDIVIDUALS, Lancet, 349(9058), 1997, pp. 1086-1092
Authors:
MOYLE GJ
Citation: Gj. Moyle, OCCURRENCE OF LYMPHOMAS DURING DDC OR DDC ZIDOVUDINE COMBINATION THERAPY IN PERSONS INFECTED WITH HIV TYPE-1/, Journal of acquired immune deficiency syndromes and human retrovirology, 13(5), 1996, pp. 464-465
Authors:
MOYLE GJ
BARTON SE
Citation: Gj. Moyle et Se. Barton, HIV-PROTEINASE INHIBITORS IN THE MANAGEMENT OF HIV-INFECTION, Journal of antimicrobial chemotherapy, 38(6), 1996, pp. 921-925
Authors:
MOYLE GJ
WALKER M
HARRIS R
WARBURG M
Citation: Gj. Moyle et al., EARLY VERSUS DELAYED ZALCITABINE (DDC) ZIDOVUDINE (ZDV) COMBINATION IN HIV-POSITIVE PERSONS WITH CD4 CELL COUNTS 300-500/MM(3) - A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (ROCHE STUDY M50003)/, AIDS, 10, 1996, pp. 49-49
Authors:
MOYLE GJ
Citation: Gj. Moyle, USE OF VIRAL RESISTANCE PATTERNS TO ANTIRETROVIRAL DRUGS IN OPTIMIZING SELECTION OF DRUG-COMBINATIONS AND SEQUENCES, Drugs, 52(2), 1996, pp. 168-185
Authors:
GAZZARD BG
MOYLE GJ
Citation: Bg. Gazzard et Gj. Moyle, INDIVIDUALIZATION OF HIV THERAPY - THE CLINICIAN PERSPECTIVE, British journal of clinical practice, 49(3), 1995, pp. 145-147
Risultati:
1-14
|